Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up

Background: Rituximab induction together with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab maintenance (RCHOP-R) resulted to significant progression-free survival (PFS) benefit in comparison to RCHOP in the EORTC20981 trial of relapsed/refractory follicular non-Hod...

Descripción completa

Detalles Bibliográficos
Autores principales: Soini, E. J. O., Martikainen, J. A., Nousiainen, T.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082160/
https://www.ncbi.nlm.nih.gov/pubmed/21135053
http://dx.doi.org/10.1093/annonc/mdq582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082160/
https://www.ncbi.nlm.nih.gov/pubmed/21135053
http://dx.doi.org/10.1093/annonc/mdq582

Ejemplares similares